For Immediate Release **May 3, 2024**

Acuitas Poster Presentations at ASGCT Annual Meeting

Vancouver, B.C. – Acuitas Therapeutics, Inc.'s Chief Scientific Officer, Dr. Ying Tam, and Vice President, Preclinical Research, Sean Semple, will deliver two poster presentations at the American Society of Gene & Cell Therapy's (ASGCT) Annual General Meeting from May 7 – 11, 2024, in Baltimore, Maryland. Several other members of the Acuitas team, including scientists and the business development team, will also attend the event.

As the global leader in lipid nanoparticle (LNP) delivery systems, members of the Acuitas team are well positioned to share recent research and data with scientific peers and colleagues from around the world who are also attending the prestigious event.

Dr. Tam's poster presentation (1243) is on Spatial Resolution of mRNA Lipid Nanoparticle-Based *In Vivo* Base Editing in the Liver of Mice and Monkeys. It explores repeated administration of mRNA lipid nanoparticles to enable effective delivery of gene editing systems following intravenous administration, offering several potential advantages compared to viral delivery, including an improved safety profile, larger payload capacity, and the opportunity to repeat dose. This describes work to evaluate spatial editing in individual cells within the liver. You can find more information on this presentation here; it will be featured on Thursday, May 9, 2024 in the Exhibit Hall.

Sean Semple's poster presentation (1755) is on Pharmacokinetics and Distribution of Lipid Nanoparticle Formulations of mRNA in Gonadal Tissues in Rat and Monkey. With the increasing use of LNP for gene editing and other RNA-based therapeutics, this presentation focuses on the essential need for a detailed understanding of LNP distribution to support the safety assessment of these therapeutics and to identify cell types for further investigation of on- and off-target editing. You can find more information on this presentation here; it will be featured on Friday, May 10, 2024 in the Exhibit Hall.

About ASGCT

The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of

medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

About Acuitas Therapeutics

Vancouver-based Acuitas Therapeutics (www.acuitastx.com) partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas' lipid nanoparticle (LNP) technology is clinically validated, enabling Alnylam Pharmaceuticals' ONPATTRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works with partners on the development of improved vaccines – such as multi-valent vaccines to prevent a range of infectious diseases (including malaria, HIV/AIDS and tuberculosis) – and on novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-